Continuity at the Head of the Management Board

Gerresheimer CEO Dr. Axel Herberg Hands Over Top Job to Uwe Röhrhoff in June

DÜSSELDORF, Germany, February 9 - Chief Executive Officer Dr. Axel Herberg (51) is not seeking
reappointment and will leave the Management Board when his contract expires
in June. The Supervisory Board has received this decision with regret and in
its meeting today appointed as Herberg's successor from June the Management
Board member of many years' standing, Uwe Röhrhoff (47).

Herberg looks back over almost twenty years in top management
with Gerresheimer. Particularly in his ten years as CEO, he has shaped the
Düsseldorf company's development into an internation­ally leading supplier to
the pharma and healthcare industry and was also instrumental in the
successful flotation of Gerresheimer AG, which is now listed on the M-Dax.
Herberg has worked side by side with his successor in a relationship of
mutual trust for many years. Röhrhoff stands for continuity and experience at
the top of the business and has already been with Gerresheimer for twenty
years. He was appointed to the Management Board in 2003 and, for example,
bore key responsibility for development of Gerresheimer's important US and
Chinese business.

"The Supervisory Board is extremely sorry that Dr. Herberg is
leaving the Management Board. He has developed Gerresheimer into a very
successful global supplier for the pharma industry. The Supervisory Board
therefore unanimously recommends that Dr. Herberg is elected to this body. We
are pleased to have Uwe Röhrhoff as the new CEO at the head of the business
from the summer. Mr Röhrhoff is ideal for this position and, thanks to his
extraordinary specialist knowledge and industry expertise, enjoys a high
level of trust among employees and customers," said Supervisory Board
Chairman Gerhard Schulze.

Axel Herberg commented: "The Gerresheimer Group is excellently
positioned. The strategy to focus on pharma and healthcare with leading
worldwide market positions has proven itself particularly during the crisis.
With Uwe Röhrhoff, who I've worked with closely for almost twenty years, the
company is in ideal hands."

In today's meeting of the Supervisory Board, Hans-Jürgen
Wiecha (47), who has been with the company for ten years, including five
years on the Management Board with responsibility for finance, was also
appointed as Chief Financial Officer for a further five years.

About Gerresheimer

Gerresheimer employs around 9,400 people in 40 locations in
Europe, Americas and Asia. In the financial year 2009, worldwide sales
totaled EUR1 billion. The product portfolio ranges from pharmaceutical
vials made of glass and plastic through to complex drug-delivery systems for
the pharma & healthcare industry. These include sterile syringes, inhalers
and other system-based approaches for safe dosage and application of
medications. The Group enjoys a leading position in markets which are
characterized by high technical and regulatory barriers.

    Contact Press

    Burkhard Lingenberg
    Director Corporate Communication & Marketing
    Phone +49-211-6181-250
    Fax +49-211-6181-241
    e-mail b.lingenberg@gerresheimer.com

    Contact Investor Relations

    Anke Linnartz
    Director Corporate Investor Relations
    Phone +49-211-6181-314
    Fax +49-211-6181-121
    e-mail a.linnartz@gerresheimer.com

Contact Press: Burkhard Lingenberg, Director Corporate Communication & Marketing, Phone +49-211-6181-250, Fax +49-211-6181-241, e-mail b.lingenberg at gerresheimer.com . Contact Investor Relations: Anke Linnartz, Director Corporate Investor Relations, Phone +49-211-6181-314, Fax +49-211-6181-121, e-mail a.linnartz at gerresheimer.com .